Recently stock market analysts have updated their consensus ratings on shares of Ares Commercial Real Estate Corporation (NYSE:ACRE). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/02/2016 – Ares Commercial Real Estate Corporation had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 13 price target on the stock.

11/06/2015 – Ares Commercial Real Estate Corporation had its “market perform” rating reiterated by analysts at Keefe, Bruyette & Woods. They now have a USD 13.5 price target on the stock.

05/08/2015 – Ares Commercial Real Estate Corporation was upgraded to “buy” by analysts at Zacks. They now have a USD 13 price target on the stock.

03/09/2015 – Ares Commercial Real Estate Corporation had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 13.5 price target on the stock.

02/04/2015 – Credit Suisse began new coverage on Ares Commercial Real Estate Corporation giving the company a “neutral” rating. They now have a USD 13.5 price target on the stock.

01/14/2015 – Ares Commercial Real Estate Corporation had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 13 price target on the stock.

03/19/2014 – Ares Commercial Real Estate Corporation was downgraded to “sell” by analysts at TheStreet.

Ares Commercial Real Estate Corporation has a 50 day moving average of 11.40 and a 200 day moving average of 11.36. The stock’s market capitalization is 330.22M, it has a 52-week low of 8.91 and a 52-week high of 13.18.

The share price of the company (NYSE:ACRE) was up +3.02%, with a high of 11.74during the day and the volume of Ares Commercial Real Estate Corporation shares traded was 157869.

View other investors thoughts on Ares Commercial Real Estate Corporation with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.